Circulating MiRNAs As Diagnostic Biomarkers for Parkinson's Disease

Overview

Journal Front Neurosci

Date 2018 Sep 21

PMID 30233304

Citations 56

Authors

Anna Elisa Roser

Lucas Caldi Gomes

Jonas Schunemann

Fabian Maass

Paul Lingor

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. Its main neuropathological hallmarks are the degeneration of dopaminergic neurons in the substantia nigra and alpha-synuclein containing protein inclusions, called Lewy Bodies. The diagnosis of idiopathic PD is still based on the assessment of clinical criteria, leading to an insufficient diagnostic accuracy. Additionally, there is no biomarker available allowing the prediction of the disease course or monitoring the response to therapeutic approaches. So far, protein biomarker candidates such as alpha-synuclein have failed to improve diagnosis of PD. Circulating microRNAs (miRNAs) in body fluids are promising biomarker candidates for PD, as they are easily accessible by non- or minimally-invasive procedures and changes in their expression are associated with pathophysiological processes relevant for PD. Advances in miRNA analysis methods resulted in numerous recent publications on miRNAs as putative biomarkers. Here, we discuss the applicability of different body fluids as sources for miRNA biomarkers, highlight technical aspects of miRNA analysis and give an overview on published studies investigating circulating miRNAs as biomarker candidates for diagnosis of PD and other Parkinsonian syndromes.

Citing Articles

Biological Function Analysis of MicroRNAs and Proteins in the Cerebrospinal Fluid of Patients with Parkinson's Disease.

Hwang J, Kim S, George N, Kwon M, Jang Y, Lee S Int J Mol Sci. 2025; 25(24.

PMID: 39769025 PMC: 11678473. DOI: 10.3390/ijms252413260.

Cohort-specific boolean models highlight different regulatory modules during Parkinson's disease progression.

Hemedan A, Satagopam V, Schneider R, Ostaszewski M iScience. 2024; 27(10):110956.

PMID: 39429779 PMC: 11489052. DOI: 10.1016/j.isci.2024.110956.

Exploring circular RNAs as biomarkers for Parkinson's disease and their expression changes after aerobic exercise rehabilitation.

de Abreu F, de Oliveira D, de Araujo Romero Ferrari S, E Silva K, Titze-de-Almeida R, Titze-de-Almeida S Funct Integr Genomics. 2024; 24(4):130.

PMID: 39069524 DOI: 10.1007/s10142-024-01409-9.

MicroRNA biomarkers as next-generation diagnostic tools for neurodegenerative diseases: a comprehensive review.

Azam H, Rossling R, Geithe C, Khan M, Dinter F, Hanack K Front Mol Neurosci. 2024; 17:1386735.

PMID: 38883980 PMC: 11177777. DOI: 10.3389/fnmol.2024.1386735.

Role of microRNAs in cognitive decline related to COVID‑19 (Review).

Bougea A, Georgakopoulou V, Lempesis I, Fotakopoulos G, Papalexis P, Sklapani P Exp Ther Med. 2024; 27(4):139.

PMID: 38476899 PMC: 10928821. DOI: 10.3892/etm.2024.12427.

References

Vickers K, Palmisano B, Shoucri B, Shamburek R, Remaley A . MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011; 13(4):423-33. PMC: 3074610. DOI: 10.1038/ncb2210. View

Cardo L, Coto E, de Mena L, Ribacoba R, Moris G, Menendez M . Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls. J Neurol. 2013; 260(5):1420-2. DOI: 10.1007/s00415-013-6900-8. View

Jamali L, Tofigh R, Tutunchi S, Panahi G, Borhani F, Akhavan S . Circulating microRNAs as diagnostic and therapeutic biomarkers in gastric and esophageal cancers. J Cell Physiol. 2018; 233(11):8538-8550. DOI: 10.1002/jcp.26850. View

Eldh M, Lotvall J, Malmhall C, Ekstrom K . Importance of RNA isolation methods for analysis of exosomal RNA: evaluation of different methods. Mol Immunol. 2012; 50(4):278-86. DOI: 10.1016/j.molimm.2012.02.001. View

Dos Santos M, Barreto-Sanz M, Correia B, Bell R, Widnall C, Perez L . miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson's disease. Oncotarget. 2018; 9(25):17455-17465. PMC: 5915128. DOI: 10.18632/oncotarget.24736. View

Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G . Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis. Neurology. 2016; 86(6):566-76. DOI: 10.1212/WNL.0000000000002350. View

Jurjevic I, Miyajima M, Ogino I, Akiba C, Nakajima M, Kondo A . Decreased Expression of hsa-miR-4274 in Cerebrospinal Fluid of Normal Pressure Hydrocephalus Mimics with Parkinsonian Syndromes. J Alzheimers Dis. 2016; 56(1):317-325. PMC: 5240577. DOI: 10.3233/JAD-160848. View

Burgos K, Malenica I, Metpally R, Courtright A, Rakela B, Beach T . Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology. PLoS One. 2014; 9(5):e94839. PMC: 4010405. DOI: 10.1371/journal.pone.0094839. View

Reed E, Latourelle J, Bockholt J, Bregu J, Smock J, Paulsen J . MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study. Neurology. 2017; 90(4):e264-e272. PMC: 5798654. DOI: 10.1212/WNL.0000000000004844. View

10.

Mo M, Xiao Y, Huang S, Cen L, Chen X, Zhang L . MicroRNA expressing profiles in A53T mutant alpha-synuclein transgenic mice and Parkinsonian. Oncotarget. 2016; 8(1):15-28. PMC: 5352072. DOI: 10.18632/oncotarget.13905. View

11.

Margis R, Margis R, R M Rieder C . Identification of blood microRNAs associated to Parkinsonĭs disease. J Biotechnol. 2011; 152(3):96-101. DOI: 10.1016/j.jbiotec.2011.01.023. View

12.

Dangla-Valls A, Molinuevo J, Altirriba J, Sanchez-Valle R, Alcolea D, Fortea J . CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. Mol Neurobiol. 2016; 54(9):6647-6654. DOI: 10.1007/s12035-016-0106-x. View

13.

Sorensen S, Nygaard A, Nielsen M, Jensen K, Christensen T . miRNA expression profiles in cerebrospinal fluid and blood of patients with acute ischemic stroke. Transl Stroke Res. 2014; 5(6):711-8. DOI: 10.1007/s12975-014-0364-8. View

14.

Junn E, Mouradian M . MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol Ther. 2011; 133(2):142-50. PMC: 3268953. DOI: 10.1016/j.pharmthera.2011.10.002. View

15.

de Planell-Saguer M, Rodicio M . Analytical aspects of microRNA in diagnostics: a review. Anal Chim Acta. 2011; 699(2):134-52. DOI: 10.1016/j.aca.2011.05.025. View

16.

Arroyo J, Chevillet J, Kroh E, Ruf I, Pritchard C, Gibson D . Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011; 108(12):5003-8. PMC: 3064324. DOI: 10.1073/pnas.1019055108. View

17.

Muller M, Kuiperij H, Claassen J, Kusters B, Verbeek M . MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging. 2013; 35(1):152-8. DOI: 10.1016/j.neurobiolaging.2013.07.005. View

18.

McAlexander M, Phillips M, Witwer K . Comparison of Methods for miRNA Extraction from Plasma and Quantitative Recovery of RNA from Cerebrospinal Fluid. Front Genet. 2013; 4:83. PMC: 3655275. DOI: 10.3389/fgene.2013.00083. View

19.

de Gonzalo-Calvo D, Vea A, Bar C, Fiedler J, Couch L, Brotons C . Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine?. Eur Heart J. 2018; 40(20):1643-1650. PMC: 6528150. DOI: 10.1093/eurheartj/ehy234. View

20.

Gehrke S, Imai Y, Sokol N, Lu B . Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature. 2010; 466(7306):637-41. PMC: 3049892. DOI: 10.1038/nature09191. View